Fallopian Tube Neoplasms: all 734 studies
Page 1 of 8. Open to participants first (128), then studies with results posted, then the rest; newest registration first within each.
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsRecruitingNCT07883798
- Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care Maintenance Treatment After First-line (1L) Platinum-based Chemotherapy in Participants With Ovarian CancerNot yet recruitingNCT07859215Phase 3
- Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Homologous Recombination Deficiency (HRD) Negative Advanced Epithelial Ovarian CancerRecruitingNCT07851025Phase 3
- Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian CancerNot yet recruitingNCT07843303Phase 2
- Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian CancerRecruitingNCT07816666Phase 3
- Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and AtorvastatinNot yet recruitingNCT07815704Phase 2
- Efficacy and Safety of BG-C9074 With Bevacizumab Compared With Bevacizumab in Adults With Ovarian, Fallopian Tube, or Primary Peritoneal CancersNot yet recruitingNCT07811271Phase 3
- A Study of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab as Maintenance Therapy in Second-Line Platinum-Sensitive Recurrent Ovarian Cancer (REJOICE-Ovarian03)Not yet recruitingNCT07791732Phase 3
- A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)RecruitingNCT07776691Phase 3
- Study of Supplemental Arginine With Chemotherapy and Immunotherapy in Platinum Resistant Ovarian, Fallopian Tube, and Peritoneal CancerNot yet recruitingNCT07772882Phase 1
- Molecular Ovarian Cancer Assessment in LatiNoAmerican PAtientsNot yet recruitingNCT07771400
- A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)RecruitingNCT07743164Phase 3
- A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α（FRα）Not yet recruitingNCT07690332
- IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerNot yet recruitingNCT07674615Phase 1
- Reirradiation and Total Ablative Strategies for Recurrent Gynecologic CancerRecruitingNCT07667192
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2RecruitingNCT07617753Phase 1/2
- An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaRecruitingNCT07604766Phase 3
- Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian CancerNot yet recruitingNCT07591831Phase 2
- Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or Lung Solid TumorsRecruitingNCT07586826Phase 2
- A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT07545460Phase 3
- IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of RecurrenceRecruitingNCT07495124Phase 2
- Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingNCT07489300Phase 2
- Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)RecruitingNCT07480954Phase 1/2
- PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal CancerRecruitingNCT07472140Phase 2/3
- The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian CancerRecruitingNCT07460180Phase 1/2
- Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian CancerNot yet recruitingNCT07432594Phase 2
- Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT07402915Phase 1
- Exploring the Effects of Hand and Foot Exercise Intervention in Older Adults With Gynecological Cancer Receiving Chemotherapy Improvement of Peripheral Neuropathy and Quality of LifeNot yet recruitingNCT07362147Not applicable
- CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian CancerRecruitingNCT07322094Phase 1/2
- The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasRecruitingNCT07285044Phase 2
- Impact of Dietary Patterns on Prognosis of Ovarian Cancer Patients During PARPi MaintenanceNot yet recruitingNCT07269574
- Losartan and Paclitaxel in Platinum Resistant Ovarian CancerNot yet recruitingNCT07265739Phase 2
- A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian CancerRecruitingNCT07213804Phase 3
- Phase II Clinical Study of Utidelone Capsule (UTD2) in Patients With Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerNot yet recruitingNCT07044349Phase 2
- A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other TherapiesRecruitingNCT07024784Phase 2
- Personalized Timing of Interval Debulking Surgery in Advanced Ovarian CancerRecruitingNCT07023484Phase 2
- Personalised Timing of Interval Debulking Surgery in Advanced Ovarian CancerRecruitingNCT07022535Phase 2
- A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)RecruitingNCT06994195Phase 3
- Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube CarcinomaRecruitingNCT06969833Not applicable
- Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT06915025Phase 3
- Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological CancersRecruitingNCT06906341Phase 2
- A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.RecruitingNCT06890338Phase 2
- Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian CancerRecruitingNCT06856499Phase 1
- An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 StudyRecruitingNCT06855706Not applicable
- A Study of PHST001 in Advanced Solid TumorsRecruitingNCT06840886Phase 1
- PARPi and Ovarian Cancer SurvivalNot yet recruitingNCT06838429
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)RecruitingNCT06824467Phase 3
- A Phase I Study of SIM0505 in Participants With Advanced Solid TumorsRecruitingNCT06792552Phase 1
- Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerRecruitingNCT06787612Phase 2
- JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerNot yet recruitingNCT06751485Phase 3
- Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian CancerRecruitingNCT06735326Phase 2
- REVITALIZE: RCT to Reduce Fatigue in Adults With Ovarian Cancer on PARP InhibitorsRecruitingNCT06710548Not applicable
- CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.RecruitingNCT06690775Phase 2
- A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab SoravtansineRecruitingNCT06682988Phase 2
- MIRRORS-FROZEN - Comparing Open Vs Robotic Surgery in the Management of Women with Complex Pelvic Adnexal Masses ≤ 8cm.RecruitingNCT06638593Not applicable
- Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian CancerRecruitingNCT06617923Phase 2
- Surgery for Relapsed Ovarian Cancer in PrecisionNot yet recruitingNCT06602063Phase 1/2
- Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersRecruitingNCT06492070Phase 2
- MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian CancerRecruitingNCT06483048Phase 1
- A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian CancersRecruitingNCT06469281Phase 1
- OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer TherapyRecruitingNCT06466382Not applicable
- Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker TestRecruitingNCT06445621
- RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 ExpressionRecruitingNCT06420973Phase 2
- Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES StudyRecruitingNCT06295965
- Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive SurgeryRecruitingNCT06290193Phase 2
- SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive SurgeryRecruitingNCT06223763
- Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerRecruitingNCT06161025Phase 2/3
- A Study of Sovilnesib in Subjects With Ovarian CancerRecruitingNCT06084416Phase 1
- First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian CancerNot yet recruitingNCT06063070Phase 2
- Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total HysterectomyRecruitingNCT06024109
- HS-20089 in Patients With Ovarian Cancer and Endometrial CancerRecruitingNCT06014190Phase 2
- A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal CancerNot yet recruitingNCT06010667
- Study to Assess GTAEXS617 in Participants With Advanced Solid TumorsRecruitingNCT05985655Phase 1/2
- MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian CancerRecruitingNCT05960630Not applicable
- Development and Management of Registry in Patients With Gynecologic Cancer in KoreaRecruitingNCT05912972
- An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and OlaparibRecruitingNCT05887609Phase 2
- Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2
- A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian CancerRecruitingNCT05801783Early Phase 1
- Huaier Granule in Patients With Stage I Primary Ovarian Fallopian Tube Cancer After Peritoneal CancerNot yet recruitingNCT05792254Not applicable
- Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal CancerRecruitingNCT05739981Phase 1/2
- Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian CancerRecruitingNCT05737303Phase 3
- Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube CancerRecruitingNCT05659381Phase 3
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/2
- Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination PhenotypeRecruitingNCT05574673
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening TrialRecruitingNCT05564377Phase 2
- Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous CarcinomaRecruitingNCT05537844
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 2
- A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line TherapyRecruitingNCT05460000Phase 2
- A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)RecruitingNCT05429970Not applicable
- Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid MalignanciesRecruitingNCT05417594Phase 1/2
- A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsRecruitingNCT05377996Phase 1/2
- Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort StudyRecruitingNCT05287451Not applicable
- Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)RecruitingNCT05281471Phase 3
- Survival Effect of Hepato-celiac Lymphadenectomy In Primary or Relapsed Ovarian CancerRecruitingNCT05236686Not applicable
- Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian CancerRecruitingNCT05231122Phase 2
- Surgery Combined with Maintenance Targeted Therapy in the Treatment of Advanced Ovarian CancerRecruitingNCT05200260Phase 2
- Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxRecruitingNCT05092373Phase 1
- A Beta-only IL-2 ImmunoTherapY StudyRecruitingNCT05086692Phase 1/2
- Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian CancerRecruitingNCT05080556Phase 2